“antibody-drug-conjugate-adc” Archives

in
Entry Author Date Location
Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals 09/14/20 Seattle
Gilead Adds “Cornerstone” Cancer Drug in $21B Immunomedics Buyout 09/14/20 San Francisco
AstraZeneca to Pay $1B to Team Up With Daiichi Sankyo Again in Cancer 07/27/20 Europe
ADC’s $233M IPO Brings It to NYSE With Cancer Drug Launch on Horizon 05/15/20 New York
ADC Therapeutics Resubmits IPO to Fuel Cancer Drug Filing, Launch Plans 04/27/20 New York
Immunomedics Triple Negative Breast Cancer Drug Wins Early FDA Nod 04/22/20 New York
Three Biotechs Raise $320M in IPOs, Two Others Pass on Wall Street 10/03/19 National
$5.8B for Nothing: AbbVie Shelves Stemcentrx Drug After Latest Flop 08/29/19 Detroit Ann Arbor
GSK’s Cancer Comeback Continues With Data for Multiple Myeloma Drug 08/23/19 National
Genmab, Mirum Pharma & Fulcrum Raise $653M in Wall Street Debuts 07/18/19 National
Dyne Therapeutics Emerges With $50M to Take On Rare Muscle Disease 04/03/19 Boston
VelosBio Emerges with $58M in Funding to Steer Cancer Drugs to Clinic 10/01/18 San Diego
FDA Puts Mersana Cancer Study on Partial Hold After Patient Death 07/19/18 Boston
Jazz Pharma, ImmunoGen Strike Up Drug Pact in Leukemia and More 08/29/17 Boston
Mersana Plans IPO to Finance Clinical Trials for Breast Cancer Drug 06/02/17 Boston
Avalon Leads $18M in Early Funding for Cancer Immunotherapy Startup 09/27/16 San Diego
NimbleGen Cofounder Opens Invenra, A “Cell-Free” Antibody Shop 11/05/14 Wisconsin
Try Then Buy? Sutro Deal Could Be Celgene’s Biggest Antibody Bet Yet 10/23/14 New York
San Diego’s Ambrx Withdraws IPO, Citing Market Conditions 06/30/14 San Diego
San Diego’s Ambrx Files for IPO to Advance Antibody-Drug Conjugates 05/05/14 San Diego
Page 1 of 1